## CTO PCI, Where Is the Benefit ? Insight from DECISION CTO study

### Seung-Jung Park, MD, PhD

Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea







# 43/M, LAD CTO with Good Collateral *No Symptom*







### 43/M, LAD CTO with Good Collateral No Symptom, Negative TMT Normal Thallium Perfusion Scan,





### **43/M, LAD CTO with Good Collateral** *No Symptom, Negative TMT Normal Thallium Perfusion Scan,*



#### Do You Want to Open ?







# 48/F, RCA CTO with Good Collateral *No Symptom*



CardioVascular Research Foundation





48/F, RCA CTO with Good Collateral No Symptom, Negative TMT Normal Thallium Perfusion Scan,



CardioVascular Research Foundation



### **48/F, RCA CTO with Good Collateral** *No Symptom, Negative TMT Normal Thallium Perfusion Scan,*



#### Do You Want to Open ?







### 75/M, RCA CTO with Good Collateral No Symptom, Medium Sized Reversible Ischemia,









### 75/M, RCA CTO with Good Collateral No Symptom, Medium Sized Reversible Ischemia, Negative TMT



#### Do You Want to Open ?





### Do You Still Want to Open ?

**43/M, 48/F** *No Symptom, No Ischemia Good Exercise performance* 

**75/M,** *No Symptom, Small Ischemic Myocardium Good Exercise Performance* 







## **PCI Classification**

Cosmetic Angioplasty

Non-Viable, Asymptomatic, Small Ischemic Myocardium, FFR >0.80, No Evidence of Ischemia, Symptomatic Angioplasty

For Angina Relieve Survival Angioplasty

Left Main and 3 Vessel-Disease

For Large Ischemic Burden





### Different Pathophysiologic Consideration of CTO Lesions

 Various Ischemic Threshold due to Various Collateral Circulation.
No ruptures ! Clinically Stable.





## **Improved Quality of Life ?**

## They Are Already Functionally Good Enough !







### **Activities of Daily Life (% Peak VO<sub>2</sub>)** in CHF Patients and Healthy Subjects

ADL1: putting on two socks, two shoes, and a vest

ADL2: folding eight towels

ADL3: putting away groceries in the cupboard

ADL4: washing up 4 dishes, 4 cups and 4 saucers

ADL5: sweeping the floor for 4 min



Eur J Appl Physiol (2011) 111:1679–1686









### *All-cause Mortality* Meta-analysis of CTO PCI (n=28,685)

Study	FCI Su	16655	- FCI	Fallu		Odds ratio
	Events	Total	Events	Total	Weight	[95%CI]
Finci	5	100	3	100	0.29	1.70 [0.32, 11.23]
Warren	0	26	0	18	0	* (excluded)
Ivanhoe	3	317	7	163	0.94	0.21 [0.04, 0.95]
Angioi	з	93	9	108	0.83	0.37 [0.06, 1.54]
Noguchi	7	134	15	92	1.74	0.28 [0.09, 0.78]
Suero	395	1491	180	514	20.22	0.67 [0.54, 0.84]
Olivari	3	286	3	83	0.47	0.28 [0.04, 2.16]
Hoye	37	567	36	304	4.50	0.52 [0.31, 087]
Drozd	7	280	5	149	0.65	0.74 [0.20, 3.01]
Arslan	19	117	37	115	3.21	0.41 [0.21, 0.80]
Aziz	9	377	12	166	1.67	0.31 [0.12, 0.83]
Valenti	17	344	17	142	2.35	0.38 [0.18, 0.83]
Labriole	7	127	2	45	0.29	1.25 [0.23, 12.81]
Chen	2	132	3	20	0.53	0.09 [0.01, 0.84]
Lee	8	251	4	82	0.60	0.64 [0.17, 3.00]
Mehran	74	1226	49	565	6.48	0.68 [0.46, 1.01]
Jolicoeur	22	213	24	133	2.72	0.52 [0.27, 1.03]
Yang	7	87	10	49	1.01	0.34 [0.10, 1.09]
Borgia	19	237	9	65	1.34	0.54 [0.22, 1.44]
Jones	26	582	44	254	6.01	0.22 [0.13, 0.38]
George S	492	10199	259	4240	35.78	0,78 [0.67, 0.91]
Yamamoto	92	1192	35	332	5.19	0.71 [0.47, 1.10]
Kim	56	2045	20	523	3.18	0.71 [0.41, 1.26]
	1210	20423	783	8262	100.00	0 52 [0 43 0 63]





Am J Cardiol. 2015;115;1367-1375



Successful CTO PCI vs. Failed PCI All Biased Registry Data







### Unadjusted Kaplan-Meier Curve Death



Lee et al. JACC Cardiovasc Interv. 2016;9:530-8, AMC CTO Registry Data (n=1,173)



Unadjusted Kaplan-Meier Curve Death or Q-wave MI



Lee et al. JACC Cardiovasc Interv. 2016;9:530-8, AMC CTO Registry Data (n=1,173)



### A SYSTEMATIC REVIEW AND META-ANALYSIS; 5,518 CTO patients (2,667 PCI and 2,851 OMT)



PCI was not significantly associated with decreased risk of MACE (pooled risk ratio =0.83, 95 % confidence interval: 0.58-1.17, p = 0.28, I2=81.8%)

Klomjit S, et al JACC Supplement March 2018

### **No Difference** in Segmental Wall Thickness, Reginal and Global LV function after CTO PCI



**Kambis Mashayekhi et al. JCIN 2018; j.jcin.2018.05.041**, A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion. The REVASC Trial (n=205, MRI study)



## Do You Believe The Survival Benefit of CTO PCI Is Different from Other PCIs ?







### COURAGE at 15 Years: No Survival Benefit for PCI





Sedlis SP, et al. N Engl J Med. 2015;373:1937



### **No Survival Benefit of PCI** Over Medications in Stable Disease

### 12 RCTs, 7182 participants

Favors PCI	Favors MT RR P
All-cause mortality	0.85 [0.71, 1.01] 0.07
Cardiac death	0.71 [0.47, 1.06] 0.09
Nonfatal MI	0.93 [0.70, 1.24] 0.61
Repeat Revascularization —	0.93 [0.76, 1.14] 0.47
Angina	0.83 [0.73, 0.94] 0.005
Å	
Risk rati	o (95% Cl)



Pursnani et al, Circ CV Intv 2012







## **No Survival Benefit !**









Survival Benefit ! CABG is Better !







### **Cumulative Mortality**



Head SJ et al. Lancet February 22, 2018 ; *Patient-level Meta-Analysis of 11,518 Patients with 11 RCTs (ERACI II, ARTS, MASS-II, SoS, SYNTAX, PRECOMBAT, FREEDOM, VA CARDS, BEST, NOBLE, and EXCEL)* 

## **MVD** with CTO lesion

*Is It More Dangerous ? Diseased Non-CTO vessel Should Supply Larger Ischemic Burden including CTO Territory, and MVD with CTO lesion is More At Risk.* 







## Higher Mortality in MVD with CTO



## Multi-vessel Disease with CTO lesion















### 73/F, 3 VD with RCA CTO lesion (SS 32, JCTO score 3)



RCA CTO

LCX disease, RCA Collateral from LAD and LCX LAD disease







## What I Did



### Complete Revascularization with Multiple DESs















### 76/M, 3 VD with LAD CTO lesion (High SS 33, JCTO score 3)



**RCA 85%** 

LCX 90%

LAD CTO







## What I Did



### **PCI for Non-CTO lesions**

### OMT for LAD CTO







## Treatment for MVD with CTO lesion

CABG
CTO PCI with Non-CTO PCI
OMT (No CTO PCI) with Non-CTO PCI







### Treatment for MVD with CTO lesion



Preliminary Data from DECISION-CTO Registry (n=2,267)

## **DECISION CTO Study**,

## **COURAGE Like Randomized Study for CTO Lesions.**

## **DECISION-CTO**



Clinical Outcomes at 3 years (Composite of Death, MI, Stroke and any Revascularization)

### **Baseline Characteristics**

	OMT (N=398)	PCI (N=417)	P value
Age (years)	62.9±9.9	62.2±10.2	0.35
Male sex	315 (81.4%)	342 (83.2%)	0.50
BMI, kg/m²	25.4±3.3	25.6±3.6	0.66
Hypertension	235 (60.7%)	261 (63.5%)	0.50
Diabetes mellitus	133 (34.4%)	132 (32.1%)	
Hypercholesterolemia	215 (55.6%)	248 (60.3%)	0.17
Current smoker	102 (26.4%)	125 (30.4%)	0.20
Previous PCI	74 (19.1%)	62 (15.1%)	0.13
Previous MI	34 (8.8%)	45 (10.9%)	0.31
Previous CABG	5 (1.3%)	4 (1.0%)	0.75
Chronic renal failure	5 (1.3%)	6 (1.5%)	0.84
LVEF, %	57.2±9.4%	57.2±9.8%	0.95

### **Baseline Characteristics**

	OMT (N=398)	PCI (N=417)	P value
<b>Clinical presentation</b>			0.58
Stable angina	290 (74.9%)	297 (72.3%)	
Unstable angina	75 (19.4%)	84 (20.4%)	
AMI	22 (5.7%)	30 (7.3%)	
Location of CTO			0.71
LAD	161 (41.6%)	183 (44.5%)	
LCX	42 (10.9%)	40 (10.2%)	
RCA	184 (47.5%)	186 (45.3%)	
Multi-vessel disease	286 (73.9%)	301 (73.3%)	0.76
SYNTAX score	21.0±9.5	21.2±9.1	0.79
J-CTO score	2.3±1.2	2.2±1.2	0.23
Number of total stents	2.0±1.4	2.4±1.3	<0.001
Total stent length, mm	53.6±39.4	71.2±40.5	<0.001

#### **ITT Population**

### Primary End Point (Death, MI, Stroke, Any Revascularization)



#### **AT Population**

### Primary End Point (Death, MI, Stroke, Any Revascularization)



### **Quality of Life Measures Over Time**



P values are for Treatment\*Time

### Clinically Meaningful Improvements

### **SAQ-Quality of Life**



### Practical Message from DECISION CTO Study

 Single Vessel CTO ;
Optimal Medical Treatment (OMT) Is Mostly Safe and Effective.

 MVD with CTO lesion : Non-CTO lesion PCI with OMT Would be An Effective Alternative for those Patients.

## Where Is the Benefit CTO PCI ?

**Symptomatic** 

## Thank You !!

and the state of the design in

summitMD.com